|View printer-friendly version|
|Kala Pharmaceuticals to Present at Upcoming Investor Conferences|
To access a live webcast and subsequent archived recording of the presentations, please visit the “Investors & Media” section on the Kala website at http://kalarx.com/.
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary Mucus Penetrating Particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid, LE, designed for ocular applications, resulting in the recent approval of INVELTYS for the treatment of inflammation and pain following ocular surgery. Kala plans to submit a New Drug Application for KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease in the second half of 2018.